Meiou Dai, Ph.D.
Education : PhD in Experimental Medicine, University of McGill, Canada.
Current research : Genome-wide CRISPR/CAS9 loss-of-function screening for new cancer drug target discovery and biomarkers of drug resistance.
Ni Wang, Ph.D.
Jun Tian, Ph.D.
Education: Ph.D. in Experimental Medicine, McGill University
Current research: Investigation of the role of COX-2 and its associated genes in BCSC-mediated tumor metastasis and drug resistance.
Dr Yun Wang
Studying synthetic lethality's in triple negative breast cancer
Dr Ting Ye
Sophie Poulet, Ph.D. Candidate
Julien Boudreault, Ph.D. Candidate
Education : M.Sc. in Molecular Biology at the University of Sherbrooke.
Current Research : The production of genetically modified cancer cell lines using the CRISPR technology and the cytotoxic study of kinase inhibitors in breast cancer.
Gang Yan, Ph.D. candidate
Education : B.Sc. in Biochemistry and Molecular Biology, Northeast Agricultural University, China.
Current research : Utilizing genome-wide Crispr/Cas9 screen based on paclitaxel to identify key genetic mutations responsible for paclitaxel resistance in triple negative breast cancer.
Yi-Ching Tsai, MSc candidate
Defining the role of CDK6 and DNA repair pathways in tumorigenesis and identify CDK4/6-dependent synthetic lethal vulnerabilities in triple negative breast cancer.
Amina Laham, PhD candidate
PhD project proposal: The role of Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) in DNA homologous recombination repair and response of cancer cells to chemotherapy
Education : Diploma in Biotechnology, Algonquin College, Canada
Program Assistant, Cancer Research Program (CRP)